To this end, we probed for AD-tau seeds at 3- and 7-days post-injection (d.p.i.)using an anti-phospho-tau (p-tau) antibody (AT8) (Fig. S3a and b) or anti-human tau antibody (HT7) (Fig. S3c and d). This evidence concerns the gene MAPT and Alzheimer disease.